Drug Sponsors

Merz to acquire medical device company Ulthera

Friday, June 27, 2014 11:09 AM

Specialty healthcare company Merz will acquire Ulthera, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its ultrasound platform technology. The merger is valued at up to $600 million in upfront cash and milestone payments.

More... »

WIRB Copernicus Group

Affymax to dissolve company

Thursday, June 26, 2014 01:52 PM

The board of directors of biopharmaceutical company Affymax has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders.

More... »

CRF Health eCOA webinar series

IMS Health acquires Cegedim’s CRM and software developer unit

Thursday, June 26, 2014 12:45 PM

By Ronald Rosenberg
CenterWatch Staff Writer

IMS Health, which in the last year has been actively making acquisitions leading up to its April IPO, has announced its intention to acquire Paris-based Cegedim’s information solutions and customer relationship management (CRM) business for approximately $520 million in cash.

More... »

AbbVie outlines rationale for Shire offer

Wednesday, June 25, 2014 02:14 PM

Following Shire’s confirmed rejection of Abbvie’s offer on June 20, AbbVie has outlined its strategic rationale for, and background to, its proposal to the board of Shire of $34.74 in cash and 0.7988 ordinary shares of New AbbVie for each Shire share. The proposal represented an indicative value of $78.63 on May 29 (the latest practicable date before the proposal was made). While this cash and share mix is valued at $77.57 per share as of June 24, any firm offer made by AbbVie under Rule 2.7 of the Code will need to be equivalent to $78.63 per share.

More... »

Lundbeck completes acquisition of Chelsea Therapeutics

Wednesday, June 25, 2014 02:06 PM

Lundbeck has completed its acquisition of Chelsea Therapeutics International for $6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional $1.50 per share upon achievement of certain sales milestones.

More... »

InVivo Therapeutics realigns R&D strategy

Wednesday, June 25, 2014 01:54 PM

As a result of an in-depth review of the company's R&D portfolio, InVivo Therapeutics is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI).

More... »

Endo to acquire Dava Pharmaceuticals

Wednesday, June 25, 2014 01:50 PM

Endo International has reached a definitive agreement to acquire Dava Pharmaceuticals, a privately held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. The acquisition enhances Endo's commercialization and development platform and is expected to be immediately accretive to Endo's 2014 adjusted earnings per share (EPS).

More... »

Dart Therapeutics changes name to Akashi Therapeutics

Wednesday, June 25, 2014 01:46 PM

Dart Therapeutics has changed its name to Akashi Therapeutics to reflect its progress in developing a pipeline of product candidates to improve the lives of children with Duchenne muscular dystrophy (DMD).

More... »

Shire confirms rejection of AbbVie proposal

Friday, June 20, 2014 01:47 PM

Shire has confirmed it has rejected the May 30 unsolicited and highly conditional proposal from AbbVie regarding a possible cash and share offer for Shire. 

More... »

Celsion completes acquisition of Egen

Friday, June 20, 2014 01:04 PM

Celsion, an oncology drug development company, has completed its acquisition of substantially all of the assets of Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes Egen’s phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs